HOME
ABOUT US
SERVICES
RESEARCH
EQUITY
DERIVATIVES
IPO
INTERNET TRADING
FTP
CONTACT US
SENSEX
55.70
0.22%
25461.00
NIFTY
193.42
0.23%
83432.89
Nasdaq
207.97
1.02%
20601.10
Nikkei 225
24.98
0.06%
39810.88
FTSE 100
-0.30
0.00%
8822.90
YOU ARE ON
Equity
Equity Analysis
Price
Gainers & Losers
Out & Under Performers
Only Buyers & Sellers
Advances & Declines
New Highs & Lows
Weightage
5 Day's Up & Down
Historical Returns
Volume
Most Active
Bulk Deals
Block Deals
Highest & Lowest Delivery
Analysis
Live Indices
Rising VDP
Rising VD & Falling Price
News Analysis
Hot Stocks
Opening Bell
Midday Review
Closing Bell
Other Market
Corporate News
Market Pulse
Economy
Company Result
FII Position
Global Markets
Current Affairs & Politics
Mutual Fund News
Market Commentry
Corporate Action
BSE Announcements
NSE Announcements
Book Closure
Board Meetings
Bonus Issues
Right Issues
Split of Face Value
Dividend Details
Delisted Companies
Change Of Name
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Quarterly Results
Financial Ratios
Share Price
MF Holdings
Price Charts
Company News
CompanyChart
Cash Flow
Share Holdings
Deliverable Volume
Historical Volume
Directors Reports
Peer Comparison
Board Meetings
Corporate Announcements
Book Closure
Bonus Issues
AGM
Other Market
FII Investments
DII Investments
World Indices
ADR Prices
Forex
Remedium Lifecare Ltd.
From Date
:
To Date
:
Source Date
Board Meeting Date
Details
27-May-2025
30-May-2025
Audited Results
17-Apr-2025
24-Apr-2025
Inter alia, to consider and approve:- 1. To Approve the Letter of Offer (LOF) for the proposed Rights Issue of 49,19,04,000 Equity Shares of Re. 1/- each, aggregating to 4919.04 lakhs for shareholders of the Company. 2. Any other item with the permission of the Chair and Majority of Directors.
01-Apr-2025
07-Apr-2025
Rights Issue
10-Feb-2025
14-Feb-2025
Quarterly Results
17-Jan-2025
22-Jan-2025
Inter alia, to consider and approve:- (1) Raising funds by way of issue of fresh equity shares through Right Issue basis along-with other matter, if any, as may be permitted under applicable laws, subject to such regulatory/statutory approvals as may be required. 2) Any other business with the permission of the Chair.
11-Nov-2024
14-Nov-2024
Quarterly Results
28-Aug-2024
04-Sep-2024
(Revised) Inter alia to consider the following:- 1. To Consider Acquisition of AirOWater Global Trading LLC, UAE:The Board will review the proposal to acquire a substantial stake in AirOWater Global Trading LLC, a pioneering entity in the production of the purest form of drinking water via Atmospheric Water Generators (AWGs). This technology, recognised as one of the most sustainable solutions to the pressing issue of global water scarcity, has successfully catered to diverse sectors including Government Institutions, Corporates, Hospitality chains, Supermarkets, Hospital chains, Educational institutions, and Community Centres. 2. To Consider issuing of Foreign Currency Convertible Bonds (FCCBs). 3. Any other business with the permission of the Chair.
27-Aug-2024
03-Sep-2024
Inter alia, to transact following business:- 1. Acquisition of a company, Airowater Global Trading LLC, UAE which is into Water Injectables for Pharma Production. 2. Consideration of issuing of Foreign Currency Convertible Bonds (FCCBs) 3. Any other business with the permission of the Chair
07-Aug-2024
14-Aug-2024
Quarterly Results (Revised)
18-Jul-2024
20-Jul-2024
Increase in Authorised Capital
15-Jul-2024
08-Aug-2024
Quarterly Results
02-Jul-2024
08-Jul-2024
Inter alia to: 1. Consider and approve the proposal for fund raising through Qualified Institutional Placement (QIP): (i) To evaluate and approve the proposal to raise funds up toRs. 200,00,00,000/- (Rupees Two Hundred Crores Only) by way of issuance of equity shares, convertible securities, or other eligible instruments to Qualified Institutional Buyers (QIBs) to finance the acquisition of Good Manufacturing Practices (GMP) assets in the Active Pharmaceutical Ingredients (API) and Intermediates space, as well as the acquisition of technology, Intellectual Property (IP), including US Drug Master File (USDMF), Certificate of Suitability to the Monographs of the European Pharmacopoeia (CEP), tech packages, and other relevant assets. (ii) To determine the quantum, terms, and conditions of the QIP, including but not limited to the pricing, titning, and other relevant aspects of the issuance. (iii) To discuss and authorise the engagement of necessary intermediaries, including investment bankers, legal advisors, and other professionals for the QIP process. 2. Consider allotment of Bonus Shares to the Equity Shareholders of the Company as on record date. 3. Consider any other matter with the approval of the Board: Any other 1natters necessary to effectively implement the fund-raising and acquisition process. The Board would also consider convening an extra-ordinary general meeting/ postal ballot process to seek approval of the shareholders in respect of the aforesaid proposal of fund raising, as required.
09-May-2024
27-May-2024
Audited Results (Revised) & Bonus issue
03-May-2024
10-May-2024
Bonus issue & Audited Results
23-Feb-2024
07-Mar-2024
Inter alia to consider acquisition of manufacturing facility near hyderabad, producing intermediates for the Pharmaceutical Industry.
06-Feb-2024
14-Feb-2024
Quarterly Results
02-Jan-2024
08-Jan-2024
Stock Split
06-Nov-2023
11-Nov-2023
Quarterly Results
28-Aug-2023
05-Sep-2023
Inter alia to transact the following business: 1. To appoint Mr. Adarsh Deepak Munjal (DIN: 07304004) as a Whole Time Director of the Company for a period of 3 years w.e.f. 05.09.2023 subject to the approval of the shareholders at the ensuing Extra Ordinary General Meeting of the company. 2. To consider and take on record the resignation of Dr. Vilas Ramkrishna Lokhande (DIN: 01228041) from the position of Whole Time Director of the Company. 3. Any other matter with the permission of the chair.
03-Aug-2023
12-Aug-2023
Quarterly Results
Page
1
of
3
Prev
||
Next
KYC Standard Document Kit of MCX-SX
NSE BSE & CDSL KYC format
ADINATH PMLA
INTERNAL_CONTROL_POLICY
RISK MANAGEMENT AND SURVELLANCE POLICY
ADINATH STOCK BROKING PVT LTD :
SEBI REGISTRATION NUMBERS : Bombay Stock Exchange(BSE): CASH -INZ000204337 & DERIVATIVE -INZ000204337 Member ID-3175 National Stock Exchange(NSE): CASH- INZ000204337 & DERIVATIVES -INZ000204337 Member ID-12805 MCX-SX Stock Exchange(MCX-SX): Currency Derivative : INZ000204337 Member ID-44400 United Stock Exchange(USE): Currency Derivative: Central Depository Services Ltd(CDSL)- IN -DP-452/2008 DP ID 12055200
ADINATH COMMODITIES :
COMMODITIES SEBI REGISTRATION NUMBERS : INZ000042629 MultiCommodity Exchange Ltd (MCX):Member ID -10140 National Commodity and Derivatives Exchange Ltd (NCDEX):Member ID -00622.
ATTENTION INVESTORS :
"Prevent unauthorised transactions in your Broking & demat account--> Update your mobile numbers/email IDs with your stock brokers & depository participate. Receive information of your transactions directly from Exchange & CDSL on your mobile/email at the end of the day......................Issued in the interest of Investors"
ATTENTION INVESTORS :
"KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary."
ATTENTION INVESTORS :
"No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."
ATTENTION INVESTORS :
1. Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. 2. Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. 3. Pay 20% upfront margin of the transaction value to trade in cash market segment 4. Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. 5. Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. "Issued in the interest of Investors"
|
Disclaimer
|
Privacy Policy
|
Feedback
|
Terms and Conditions
|
Careers
|
Investor Grievances
|
Download
|
Investor Protection
|
SCORES
|
Site Map
Investor Charter - DP
|
Investor Charter - Stock Broker
|
e-voting
|
Investor Education
|
Client Collateral Details
|
NSDL eVoting
|
Advisory for investors
Useful links:
NSE
|
BSE
|
MCX-SX
|
CDSL
|
SEBI
|
MCX
|
NCDEX
|
FMC
|
Smart ODR
SEBI Registration No.INZ000042629
Copyright © 2011 Adinath Stock Broking Pvt Ltd Designed, Developed & Content Powered By
●
●
●
Accord Fintech Pvt.Ltd.
CLOSE
X
Filing complaints on SCORES
Easy & quick
>
Register on SCORES portal
(https://scores.sebi.gov.in)
>
Mandatory details for filing complaints on SCORES
Name
PAN
Address
Mobile Number
E-mail ID
>
Benefits:
Effective communication
Speedy redressal of the grievances